Statistics from Altmetric.com
The management of acute venous thromboembolism (VTE) in patients with active cancer is challenging. In the landmark CLOT study,1 low-molecular-weight heparin (LMWH) halved the incidence of recurrent VTE compared to vitamin K antagonists (VKAs) with similar rates of major bleeding. These observations were confirmed in additional smaller studies, which, together with the more stable pharmacokinetics of LMWH, have led to the recommendation of LMWH over VKAs.2 ,3 Notwithstanding the favourable profile of LMWH, VKAs remain widely used worldwide. In this context, the results of the CATCH study were eagerly awaited.
The CATCH study was a two-arm parallel design, randomised, open-label study …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.